Vaxcyte PCVX Cash Flow Statement (2019-2026)

NASDAQ PCVX
$61.10 -0.07 (-0.11%)
As of: Sep 4, 2026 · 1:32 PM EDT
Reported Financials

Vaxcyte Quarterly Cash Flow Statement

Periods 30 quarters
Latest Jun 2026

Vaxcyte reported cash from operations of -$232.47M and free cash flow of -$232.55M for the quarter ended Jun 2026, down 91.9% year over year. This cash flow statement covers 30 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-26.86M-29.75M-39.81M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M-277.02M
Share-based Compensation
6.32M0.73M4.10M5.89M6.65M7.01M9.65M12.54M24.30M13.35M17.63M21.56M21.27M24.37M30.61M36.93M35.31M36.00M37.96M41.24M
Gains from Investment Securities
Asset Writedowns and Impairment
0.06M0.16M
Cash from Operations
-28.41M-51.09M-27.70M-39.13M-38.55M-65.22M-47.69M-62.74M-57.55M-128.81M-159.12M-121.39M-60.71M-111.40M-166.27M-121.17M-143.31M-224.83M-280.62M-232.47M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
-1.47M2.57M1.79M1.56M1.67M1.60M5.99M11.84M14.57M2.37M10.99M9.93M6.10M11.68M4.91M4.49M2.26M2.76M3.11M2.72M
Depreciation & Amortization (CF)Depreciation & Amortization
0.51M0.46M0.58M0.61M0.68M0.96M0.71M0.75M0.81M0.89M1.00M1.35M1.79M2.86M2.96M2.88M3.06M7.50M2.95M3.00M
Change in Working Capital
Change in Account Payables
1.50M-18.07M-1.93M2.71M-1.35M3.47M1.79M2.26M0.69M6.48M5.67M-10.71M8.31M31.31M-29.16M9.53M17.88M21.67M-0.27M31.55M
Change in Accured Expenses
4.93M-3.82M-2.19M3.74M3.92M1.69M3.04M0.20M2.51M30.55M-7.97M-27.00M8.63M-9.32M-14.42M4.55M5.95M9.89M-15.57M6.20M
Other Working Capital Changes
9.94M-3.45M-5.62M1.21M1.42M4.14M4.70M-0.01M-0.56M-22.00M4.96M-8.60M6.17M39.36M16.00M-1.36M-1.40M33.14M8.74M-13.67M
Investing Activities
Capital Expenditures
1.72M1.38M2.92M0.94M0.84M1.14M5.61M-1.45M6.65M5.25M13.72M-0.26M4.95M4.02M5.42M1.81M3.82M2.65M6.34M0.08M
Sales of Property, Plant and Equipment
0.03M0.01M
Change in Acquisitions & Divestments
37.00M42.50M59.55M30.50M46.14M32.50M40.16M95.84M232.92M242.96M242.32M299.67M327.70M263.55M438.49M394.48M350.20M347.97M340.63M398.46M
Cash from Investing Activities
-18.47M0.08M49.67M26.16M34.71M-35.95M-448.10M-333.56M22.28M-13.93M-451.07M-80.41M-917.02M-557.17M123.32M77.74M121.17M115.12M-233.41M147.72M
Financing Activities
Other financing activities
0.49M1.57M0.28M0.32M1.76M3.56M0.50M0.88M2.15M4.11M5.02M4.40M11.74M5.98M6.05M3.23M0.31M3.42M9.03M7.76M
Debt Issuance and Repayment
Long-Term Debt Issuances
Change in Capital Stock
Net Shares Issued and Repurchased
1.62M0.06M0.05M0.04M0.04M
Net Equity Issued and Repurchased
7.11M6.79M3.12M49.00M43.12M2.06M41.79M49.00M-0.05M106.51M89.46M-0.03M264.20M
Misc.
Cash from Financing Activities
7.60M8.75M111.02M49.88M44.02M656.63M41.56M546.97M48.55M2.73M818.20M110.37M1,515.04M4.91M0.76M2.52M-3.67M2.41M601.58M5.70M
Exchange Rate Effect
0.33M-0.80M-0.23M-0.48M0.05M0.80M0.02M-0.08M1.05M-7.68M6.06M-1.41M-5.58M1.35M1.17M0.80M0.29M0.18M-0.66M1.40M
Change in Cash
-38.95M-43.06M132.76M36.43M40.23M556.26M-454.21M150.58M14.33M-147.68M214.06M-92.84M531.73M-662.31M-41.03M-40.11M-25.52M-107.12M86.88M-77.65M
Free Cash Flow
-30.13M-52.48M-30.62M-40.06M-39.39M-66.36M-53.30M-61.30M-64.19M-134.06M-172.84M-121.13M-65.66M-115.42M-171.70M-122.98M-147.13M-227.49M-286.97M-232.55M
Net Cash Flow
-39.28M-42.26M132.98M36.92M40.17M555.46M-454.23M150.66M13.28M-140.00M208.00M-91.43M537.31M-663.66M-42.20M-40.91M-25.81M-107.30M87.55M-79.05M